CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 104 enrolled
Drug / intervention
ABT-493/ABT-530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02651194
NCT02651194Phase 3Completed
CompareCT.gov

A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

AbbVie·interventional·Posted Jan 8, 2016·Updated Oct 16, 2017

In Brief

A Phase 3 clinical trial evaluating ABT-493/ABT-530 for Chronic Hepatitis C Virus (HCV) Infection. Completed, enrolled 104 participants.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus (HCV) Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 8, 2016
Enrollment StartDec 1, 2015
Primary CompletionOct 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.5 years ago

Interventions

ABT-493/ABT-530drug

Tablet; ABT-493 coformulated with ABT-530